No Data
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207
No Data
No Data
factors that put the rise on are not from a rebound but from news, either way the price is above the price before financial reporting
